# Neoadjuvant Herceptin in Patients With Breast Cancer

> **NCT00133796** · PHASE2 · TERMINATED · sponsor: **Mothaffar Rimawi** · enrollment: 40 (actual)

## Conditions studied

- BREAST CANCER

## Interventions

- **DRUG:** Herceptin

## Key facts

- **NCT ID:** NCT00133796
- **Lead sponsor:** Mothaffar Rimawi
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2001-10
- **Primary completion:** 2005-09
- **Final completion:** 2007-04
- **Target enrollment:** 40 (ACTUAL)
- **Why stopped:** Closed to accrual 4/19/2006 / Study doesn't qualify for reporting.
- **Last updated:** 2017-02-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00133796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00133796, "Neoadjuvant Herceptin in Patients With Breast Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00133796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*